FrancophonIA/ELRC3.0 huggingface dataset:
English: Corlentor therefore reduces or prevents the symptoms of angina.
Estonian: Sellega vähendab Corlentor stenokardiasümptomeid või ennetab neid.
English: Also, the doctor should consider stopping treatment if the medicine has only a limited effect on reducing angina symptoms or reducing the heart rate within 3 months.
Estonian: Arst peab kaaluma ravi lõpetamist ka siis, kui ravim leevendab sümptomeid või vähendab südame löögisagedust 3 kuu jooksul üksnes piiratud määral.
English: In this study, a specific subgroup of patients who had symptomatic angina had a small but significant increase in the combined risk of cardiovascular death or non-fatal heart attack with Corlentor compared with placebo (3.4% vs 2.9% yearly incidence rates).
Estonian: Selles uuringus täheldati teatavas sümptomaatilise stenokardiaga patsientide alagrupis Corlentori puhul väikest, aga olulist kardiovaskulaarse surma või mittefataalse südameinfarkti riski suurenemist võrreldes platseeboga (aastane esinemuse määr 3,4% vs 2,9%).
English: The symptoms of heart failure are caused by the heart not pumping enough blood around the body.
Estonian: Südamepuudulikkuse sümptomid tulenevad sellest, et süda ei suuda pumbata organismi piisaval hulgal verd.
English: The most common side effect with Corlentor ( which may affect more than 1 in 10 people) is luminous phenomena or ‘phosphenes' (a temporary brightness in the field of vision).
Estonian: Corlentori kõige sagedam kõrvalnäht (võib esineda enam kui 1 patsiendil 10st) on helendav nägemisfenomen (fosfeenid, nägemisvälja mööduv helendus).
English: By lowering the heart rate, Corlentor reduces the stress on the heart, thereby slowing the progression of heart failure and improving symptoms.
Estonian: Südame löögisagedust aeglustades vähendab Corlentor südame koormust, pidurdades südamepuudulikkuse kulgu ja leevendades sümptomeid.
English: Corlentor is also used in patients with long-term heart failure (when the heart cannot pump enough blood to the rest of the body) who have a normal heart rhythm and whose heart rate is at least 75 beats per minute.
Estonian: Corlentorit kasutatakse ka pikaajalise südamepuudulikkusega (süda ei suuda pumbata organismi piisaval hulgal verd) patsientidel, kellel on normaalne südamerütm ja südame löögisagedus on vähemalt 75 lööki minutis.
English: Results showed that Corlentor was more effective than placebo at preventing death due to disease of the heart or blood vessels or hospitalisation due to worsening heart failure: 24.5% (793 out of 3,241) of patients treated with Corlentor died or were hospitalised due to worsening heart failure, compared with 28.7% (937 out of 3,264) of patients receiving placebo.
Estonian: Corlentor ennetas kardiovaskulaarset surma või haiglaravi progresseerunud südamepuudulikkuse tõttu efektiivsemalt kui platseebo: patsiente, kes surid või said haiglaravi progresseerunud südamepuudulikkuse tõttu, oli Corlentoriga ravitud patsientidest 24,5% (793 patsienti 3241st) ja platseebot kasutanud patsientidest 28,7% (937 patsienti 3264st).
English: Corlentor is a heart medicine used to treat the symptoms of long-term stable angina (pains to the chest, jaw and back, brought on by physical effort) in adults with coronary artery disease (disease of the heart caused by the obstruction of the blood vessels that supply blood to the heart muscle).
Estonian: Corlentor on südameravim, mida kasutatakse pikaajalise stabiilse stenokardia (füüsilise pingutuse tagajärjel tekkiv rindkere-, lõua- ja seljavalu) sümptomaatiliseks raviks südame isheemiatõvega (südamelihast verega varustavate veresoonte ummistusest põhjustatud haigus) täiskasvanutel.
English: A sixth study compared Corlentor with placebo in 19,102 patients with coronary artery disease and without clinical heart failure.
Estonian: Kuuendas uuringus võrreldi Corlentorit platseeboga 19 102 patsiendil, kellel oli südame isheemiatõbi, aga ei olnud kliinilist südamepuudulikkust.
English: In a fourth study in 889 patients, Corlentor was more effective than placebo, when both were added to atenolol.
Estonian: Neljandas uuringus, milles osales 889 patsienti, oli atenoloolile lisatud Corlentor efektiivsem kui atenoloolile lisatud platseebo.
English: Corlentor was compared with placebo in one main study involving over 6,500 patients with long-term moderate to severe heart failure.
Estonian: Corlentorit võrreldi platseeboga ühes põhiuuringus, milles osales enam kui 6500 mõõduka või raske pikaajalise südamepuudulikkusega patsienti.
English: How is Corlentor used?
Estonian: Kuidas Corlentorit kasutatakse?
English: How does Corlentor work?
Estonian: Kuidas Corlentor toimib?
English: The recommended starting dose is 5 mg twice a day with meals, which the doctor may increase to 7.5 mg twice a day or decrease to 2.5 mg (half a 5-mg tablet) twice a day depending on the patient's heart rate and symptoms.
Estonian: Arst võib annust patsiendi südame löögisagedusest ja sümptomitest olenevalt suurendada 7,5 mg-ni kaks korda ööpäevas või vähendada 2,5 mg-ni (pool 5 mg tabletti) kaks korda ööpäevas.
English: When used for angina, treatment should be stopped if symptoms do not improve after 3 months.
Estonian: Stenokardiapatsientidel tuleb ravi peatada, kui 3-kuulise ravi järel sümptomid ei leevene.
English: It must not be used in women who are pregnant, breast-feeding or by women who could become pregnant and who are not using appropriate contraceptives.
Estonian: Seda ei tohi kasutada raseduse ega imetamise ajal; samuti ei tohi ravimit kasutada fertiilses eas naised, kes ei kasuta efektiivseid rasestumisvastaseid vahendeid.
English: Corlentor was compared with placebo (a dummy treatment) and other treatments in five main studies involving over 4,000 adults with long-term stable angina.
Estonian: Corlentorit võrreldi platseeboga (näiv ravim) ja teiste ravimitega viies põhiuuringus, milles osales enam kui 4000 pikaajalise stabiilse stenokardiaga täiskasvanut.
English: The medicine is used in patients who have a normal heart rhythm, and whose heart rate is at least 70 beats per minute.
Estonian: Ravimit kasutatakse patsientidel, kellel on normaalne südamerütm ja südame löögisagedus on vähemalt 70 lööki minutis.
English: However, the use was later restricted to patients whose heart rate is at least 70 beats per minute.1
Estonian: Hiljem piirati selle kasutamine aga ainult patsientidega, kelle südame löögisagedus on vähemalt 70 lööki minutis1.
English: What benefits of Corlentor have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Corlentori kasulikkus?
English: Results showed that the medicine was more effective than placebo in one of the studies in 360 patients.
Estonian: Põhiuuringute tulemustest nähtus, et ühes uuringus (360 patsienti) oli ravim efektiivsem kui platseebo.
English: For the full list of restrictions with Corlentor, see the package leaflet.
Estonian: Corlentori kohta teatatud piirangute täielik loetelu on pakendi infolehel.
English: An overview of Corlentor and why it is authorised in the EU
Estonian: Ülevaade ravimist Corlentor ja ELis müügiloa väljastamise põhjendus
English: It was as effective as atenolol (a beta blocker) in a study of 939 patients and as effective as amlodipine (another medicine used to treat angina) in a study of 1,195 patients.
Estonian: Uuringus, milles osales 939 patsienti, oli Corlentor sama efektiivne kui atenolool (beetablokaator), ning teises uuringus (1195 patsienti) oli see sama efektiivne kui amlodipiin (samuti stenokardiaravim).
English: For the treatment of angina, Corlentor was originally authorised for patients whose heart rate is at least 60 beats per minute.
Estonian: Stenokardia ravis oli Corlentor esmase müügiloa alusel näidustatud patsientidele, kelle südame löögisagedus on vähemalt 60 lööki minutis.
English: For the full list of all side effects reported with Corlentor, see the package leaflet.
Estonian: Corlentori kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The active substance in Corlentor, ivabradine, works by blocking the ‘If currents' in the sinus node, the ‘pacemaker' for the heart that controls the heart's contractions and regulates the heart rate.
Estonian: Corlentori toimeaine ivabradiin blokeerib siinussõlmes (südame kokkutõmbeid juhtiv ja löögisagedust reguleeriv südamepiirkond ehk loomulik rütmur) tekkiva nn If-voolu.
English: It is used in combination with standard therapy including beta blockers, or in patients who cannot be treated with beta blockers.
Estonian: Seda kasutatakse koos beetablokaatoreid sisaldava tavaraviga või patsientidel, keda ei saa ravida beetablokaatoritega.
English: Bradycardia (slow heart rate) is common (it may affect up to 1 in 10 people).
Estonian: Sage kõrvalnäht (võib esineda kuni 1
English: It is used in those who cannot be treated with beta blockers (another type of medicine to treat angina) or in combination with a beta blocker in patients whose disease is not controlled by beta blockers alone.
Estonian: Seda kasutatakse patsientidel, keda ei saa ravida beetablokaatoritega (samuti stenokardiaravim), või kombinatsioonis beetablokaatoriga patsientidel, kellel ainult beetablokaatorite kasutamine ei ole tulemusi andnud.
English: The symptoms of angina are caused by the heart not receiving enough oxygenated blood.
Estonian: Stenokardiasümptomeid põhjustab südame ebapiisav varustatus hapnikurikka verega.
English: 25 May 2012
Estonian: 25. mai 2012
English: Written explanations were provided by the applicant on 13 September 2011 and 11 January 2012.
Estonian: Taotleja esitas kirjalikud selgitused 13. septembril 2011 ja 11. jaanuaril 2012.
English: The application was submitted to Ireland as reference Member State and Austria, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Greece, Spain, Finland, France, Hungary, Latvia, Lithuania, Malta, the Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia and Sweden as concerned Member States, as well as Iceland and Norway.
Estonian: Viiteliikmesriik oli Iirimaa ning asjaomased liikmesriigid Austria, Bulgaaria, Eesti, Hispaania, Kreeka, Küpros, Leedu, Läti, Madalmaad, Malta, Poola, Portugal, Prantsusmaa, Rootsi, Rumeenia, Slovakkia, Sloveenia, Soome, Taani, Tšehhi Vabariik ja Ungari ning Island ja Norra.
English: International non-proprietary name (inn): doramectin
Estonian: Rahvusvaheline mittekaubanduslik nimetus (INN): doramektiin
English: The final opinion was converted into a Decision by the European Commission on 25 May 2012.
Estonian: Lõplik arvamus kinnitati Euroopa Komisjoni otsusena 25. mail 2012.
English: The decentralised procedure started on 26 February 2010.
Estonian: Detsentraliseeritud menetlus algas 26. veebruaril 2010.
English: The Committee appointed Dr Michael Holzhauser-Alberti as rapporteur and Dr David Murphy as co-rapporteur.
Estonian: Veterinaarravimite komitee määras hindajaks dr Michael Holzhauser-Alberti ja kaashindajaks dr David Murphy.
English: Doramectin is a macrocyclic lactone and is closely related to ivermectin.
Estonian: Doramektiin on makrotsükliline laktoon ja on väga lähedane ivermektiinile.
English: Veterinary Medicines and Product Data Management
Estonian: Veterinaarravimite ja ravimiteabe halduse osakond
English: Potential serious risks were identified during the decentralised procedure by two concerned Member States regarding the environmental risk assessment (the Netherlands and France) and regarding the proposed withdrawal period for cattle (the Netherlands).
Estonian: Kaks asjaomast liikmesriiki tõstatasid detsentraliseeritud menetluse ajal võimaliku suure riski küsimuse seoses keskkonnariski hindamise (Madalmaad ja Prantsusmaa) ja veiste keeluaja ettepanekuga (Madalmaad).
English: Both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods.
Estonian: Mõlemal ainel on lai antiparasitaarne toimespekter, mis tekitab nematoodidel ja parasitaarsetel artropoodidel sarnase paralüüsi.
English: The referral procedure started on 5 May 2011.
Estonian: Esildise menetlemine algas 5. mail 2011.
English: The list of product names concerned is given in Annex I. The scientific conclusions are provided in Annex II, together with the amendments to the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State in the Annex III.
Estonian: Asjaomased raviminimetused on esitatud I lisas, teaduslikud järeldused II lisas ning viiteliikmesriigis muudetud ravimi omaduste kokkuvõte, märgitus ja pakendi infoleht III lisas.
English: Article 33(4) of Directive 2001/82/EC, as amended
Estonian: 1 Muudetud direktiivi 2001/82/EÜ artikli 33 lõige 4.
English: On 26 April 2011 the reference Member State, Ireland, referred the matter to the CVMP pursuant to Article 33(4) of Directive 2001/82/EC.
Estonian: 26. aprillil 2011 tegi viiteliikmesriik Iirimaa Euroopa Ravimiametile direktiivi 2001/82/EÜ artikli 33 lõike 4 kohase esildise.
English: The applicant, Pfizer Limited, submitted an application for a decentralised procedure for the above mentioned veterinary medicinal product in the framework of Article 32 of Directive 2001/82/EC, as amended.
Estonian: Taotleja Pfizer Limited esitas muudetud direktiivi 2001/82/EÜ artikli 32 kohaselt veterinaarravimi Prontax 10 mg/ml detsentraliseeritud menetluse taotluse.
English: Prontax 10 mg/ml solution for injection for cattle, sheep and pigs (and associated names) contains doramectin.
Estonian: Prontax 10 mg/ml süstelahus veistele, lammastele ja sigadele (ja sarnased nimetused) sisaldab doramektiini.
English: Opinion following an Article 33(4)F F referral for Prontax 10 mg/ml solution for injection for cattle, sheep and pigs and associated names EMA/281970/2012
Estonian: Arvamus pärast artikli 33 lõike 4F F kohast esildist Prontax 10 mg/ml süstelahus veistele, lammastele ja sigadele ja sarnased nimetused EMA/421484/2012
English: Therefore, CVMP adopted a positive opinion on 8 February 2012 recommending the granting of a Marketing Authorisation for Prontax 10 mg/ml solution for injection for cattle, sheep and pigs and associated names.
Estonian: Seetõttu võttis veterinaarravimite komitee 8. veebruaril 2012 vastu positiivse arvamuse, soovitades anda veterinaarravimi Prontax 10 mg/ml süstelahus veistele, lammastele ja sigadele ja sarnaste nimetuste müügiloa.
English: referral for Prontax 10 mg/ml solution for injection for cattle, sheep and pigs and associated names
Estonian: Prontax 10 mg/ml süstelahus veistele, lammastele ja sigadele ja sarnased nimetused
English: Based on evaluation of the currently available data, the CVMP considered that the benefit-risk profile of Prontax 10 mg/ml solution for injection for cattle, sheep and pigs and associated names is deemed to be positive provided that the recommended risk mitigation measures are added to the product information regarding risk to aquatic organisms and dung fauna and the withdrawal period for meat and offal in cattle is set at 70 days.
Estonian: pidada positiivseks, kui ravimiteabele lisatakse soovitatavad riski leevendamise meetmed riskide vähendamiseks veeorganismidele ja sõnnikufaunale ning veiseliha ja -rupsi puhul kehtestatakse keeluaeg 70 päeva.
English: MA (EU) number
Estonian: Müügiloa nr Euroopa Liidus (Väljamõeldud) nimetus
English: • anaemia;
Estonian: • aneemia;
English: After training, the patient or carer can give the infusion at home, if their doctor believes it is appropriate.
Estonian: Pärast väljaõpet võib patsient või hooldaja infundeerida ravimit kodus, kui arst peab seda kohaseks.
English: Cerezyme is usually given by infusion every two weeks.
Estonian: Cerezymet manustatakse tavaliselt infusioonina iga kahe nädala järel.
English: The patients must have symptoms that are not affecting the nervous system, including one or more of the following conditions:
Estonian: Patsientidel peavad olema sümptomid, mis ei mõjuta närvisüsteemi, sealhulgas vähemalt üks järgmistest haigustest:
English: The first few infusions should be given slowly, but after these, the speed of infusion can be increased under the supervision of a doctor or nurse.
Estonian: Esimesed infusioonid tuleb manustada aeglaselt, kuid seejärel võib arsti või meditsiiniõe järelevalve all infusioonide manustamise kiirust suurendada.
English: • an enlarged liver or spleen.
Estonian: • suurenenud maks või põrn.
English: • thrombocytopenia (low blood platelet counts);
Estonian: • trombotsütopeenia (vereliistakute vähesus);
English: This is an acceptable number because the disease is rare.
Estonian: Et seda haigust esineb harva, on see arv piisav.
English: The dose and how often the infusions are given need to be adjusted according to each individual patient's symptoms and response to treatment.
Estonian: Annust ja infusioonide sagedust peab kohandama vastavalt iga patsiendi sümptomitele ja ravivastusele.
English: For type 1 Gaucher disease, Cerezyme has been studied in three studies involving a total of 40 patients.
Estonian: I tüüpi Gaucher' tõve korral uuriti Cerezymet kolmes uuringus, milles osales kokku 40 patsienti.
English: The Committee decided that Cerezyme's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Cerezyme kasulikkus on suurem kui sellega kaasnevad riskid, ning soovitas anda ravimi müügiloa.
English: This document is a summary of the European public assessment report (EPAR) for Cerezyme.
Estonian: Käesolev dokument on ravimi Cerezyme Euroopa avaliku hindamisaruande kokkuvõte.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cerezyme to Genzyme Europe B.V. on 17 November 1997.
Estonian: Euroopa Komisjon andis Cerezyme müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Genzyme Europe B.V.
English: For more information about treatment with Cerezyme, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cerezymega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For type 3 Gaucher disease, which is extremely rare, the company presented data from published articles and from a special register of Gaucher disease patients.
Estonian: Väga harva esineva III tüüpi Gaucher' tõve kohta esitas ettevõte andmeid avaldatud publikatsioonidest ja Gaucher' tõbe põdevate patsientide eriregistrist.
English: Cerezyme is used for the long-term treatment of patients with Gaucher disease.
Estonian: Cerezymet kasutatakse Gaucher' tõvega patsientide pikaajaliseks raviks.
English: Other information about Cerezyme:
Estonian: Muu teave Cerezyme kohta
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cerezyme.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Patients can develop antibodies (proteins that are produced in response to Cerezyme and can affect treatment) and they should be monitored for any allergic reactions to Cerezyme.
Estonian: Patsientidel võivad tekkida antikehad (reaktsioonina Cerezymele tekkivad valgud, mis võivad mõjutada ravi) ja patsiente tuleb allergiliste reaktsioonide suhtes jälgida.
English: The most common side effects with Cerezyme (seen in between 1 and 10 patients in 100) are dyspnoea (difficulty breathing), coughing, urticaria (hives) or angioedema (swelling beneath the skin), pruritus (itching), rash and hypersensitivity (allergic) reactions.
Estonian: Cerezyme kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on düspnoe (hingamisraskus), köha, urtikaaria (nõgestõbi) ja angioödeem (nahaalune turse), kihelus, lööve ja ülitundlikkuse (allergia) reaktsioonid.
English: The studies have shown that Cerezyme is as safe and effective as alglucerase in controlling the symptoms of Gaucher disease.
Estonian: Uuringud on näidanud, et Cerezyme on Gaucher' tõve sümptomite leevendamisel sama ohutu ja efektiivne kui alglütseraas.
English: The studies compared the ability of Cerezyme and alglucerase to control the symptoms of the disease, such as increasing the number of red blood cells and platelets in the blood, and decreasing the size of the liver and spleen.
Estonian: Uuringutes võrreldi Cerezyme ja alglütseraasi toimet selliste haigussümptomite reguleerimisel nagu punaliblede ja vereliistakute arvu suurendamine veres ning maksa ja põrna suuruse vähendamine.
English: Imiglucerase, the active substance in Cerezyme, is a copy of this enzyme, which is produced by a method known as ‘recombinant DNA technology': the enzyme is made by a cell that has received a gene (DNA), which enables it to produce the enzyme.
Estonian: Cerezyme toimeaine imiglütseraas on inimese ensüümi koopia, mida valmistatakse rekombinant-DNA-tehnika abil: ensüümi toodab rakk, millele on lisatud selle ensüümi teket võimaldav geen (DNA).
English: Cerezyme is a powder that is made up into a solution for infusion (a drip into a vein).
Estonian: Cerezyme on pulber, millest valmistatakse infusioonilahus (veeni tilgutatav lahus).
English: It has also been shown that patients may safely switch from alglucerase to Cerezyme treatment.
Estonian: On tõestatud ka see, et patsiendid võivad ilma lisariskideta üle minna alglütseraasi manustamiselt Cerezyme manustamisele.
English: What is Cerezyme?
Estonian: Mis on Cerezyme?
English: Cerezyme should not be used in people who may be hypersensitive (allergic) to imiglucerase or any of the other ingredients.
Estonian: Cerezymet ei tohi kasutada patsiendid, kes võivad olla imiglütseraasi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: Without the enzyme, glucosylceramide builds up in the body, typically in the liver, spleen and bone marrow, which produces the symptoms of the disease: anaemia (low red blood cell counts), tiredness, easy bruising and a tendency to bleed, an enlarged spleen and liver, and bone pain and breaks.
Estonian: Ilma ensüümita koguneb glükosüültseramiid organismi, tavaliselt maksa, põrna ja luuüdisse, ning põhjustab järgmiste haigussümptomite teket: aneemia (kehvveresus), väsimus, verevalumite kerge teke ja kalduvus verejooksudele, suurenenud maks ja põrn, luuvalu ja luumurrud.
English: For the full list of all side effects reported with Cerezyme, see the package leaflet.
Estonian: Cerezyme kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Gaucher disease is a rare inherited disorder, in which people do not have enough of an enzyme called acid beta-glucosidase, which normally breaks down a fatty waste product called glucosylceramide.
Estonian: Gaucher' tõbi on haruldane pärilik haigus, mille korral ei ole patsientidel piisavalt ensüümi beetaglükosidaashapet, mis tavaliselt lõhustab rasvainejäägi glükosüültseramiidi.
English: Patients with Gaucher disease should be managed by doctors who are knowledgeable about the disease's treatment.
Estonian: Gaucher' tõvega patsiente peab ravima selle haiguse ravis kogenud arst.
English: What is the risk associated with Cerezyme?
Estonian: Mis riskid Cerezymega kaasnevad?
English: Why has Cerezyme been approved?
Estonian: Miks Cerezyme heaks kiideti?
English: Cerezyme imiglucerase
Estonian: Cerezyme imiglütseraas
English: Imiglucerase replaces the missing enzyme in Gaucher disease, helping to break down glucosylceramide and stopping it building up in the body.
Estonian: Imiglütseraas asendab patsiendil Gaucher' tõve korral puuduvat ensüümi ning aitab lagundada glükosüültseramiidi ja takistab selle kogunemist organismi.
English: Gaucher disease has previously been treated using an enzyme called alglucerase, which was prepared from human placentas.
Estonian: Gaucher' tõbe on varem ravitud inimese platsentast valmistatud ensüümi alglütseraasiga.
English: The full EPAR for Cerezyme can be found here.
Estonian: Euroopa avaliku hindamisaruande täistekst Cerezyme kohta on siin.